Research data from laboratories needs to be converted at a faster rate into clinical practice to diagnose and treat patients.
By Callum Bir, Director, Life Sciences, Oracle Asia Pacific .
The research and clinical care process has fundamentally changed in recent years. When it comes to drugs and therapeutic programs, one size no longer fits all and the traditional practice of reactive medicine with treatment selected by ‘trial and error’ will no longer suffice. Numerous factors have contributed to this phenomenon.The population is aging rapidly and Asia has been singled out as the world’s most rapidly aging region. By 2050, Asia is expected to house almost two-thirds of the world’s population over 60 years of age.
To exacerbate the situation, the number of chronic diseases such as heart attack, stroke, diabetes, respiratory disease and cancer has grown significantly. The World Health Organization (WHO) projects that by 2015, more than 70% of the people who will die from such diseases will be from Asia Pacific. This amounts to 270 million deaths out of 388 million deaths globally.In order to deliver effective treatment and high-quality care, the health sciences industry is beginning to recognize that research data from laboratories needs to be converted at a faster rate into clinical practice to diagnose and treat patients. The process of applying molecular insights from laboratory discovery to clinical care is known as translational medicine. This represents a paradigm shift in the biomedical research enterprise and is regarded as the future of healthcare.
(Read More) http://www.pharmaasia.com/article-6950-translatingbenchsideresearchintobedsidereality-Asia.html
No comments:
Post a Comment